Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Ascertaining infectious disease burden through primary care clinic attendance among young Aboriginal children living in four remote communities in Western Australia

Improved public health measures targeting bacterial skin infections are needed to reduce this high burden of skin infections in Western Australia

Research

Optimising the use of linked administrative data for infectious diseases research in Australia

Increased collaboration and engagement across all sectors can optimise the use of linked data to help reduce the burden of infectious diseases

Research

Infection characteristics and treatment of Staphylococcus aureus bacteraemia at a tertiary children's hospital

There is a wide spectrum of disease severity in paediatric Staphylococcus aureus bacteraemia

Research

Duplex quantitative PCR assay for detection of haemophilus influenzae that distinguishes fucose-and protein d-negative strains

Developed a specific Haemophilus influenzae quantitative PCR (qPCR) that also identifies fucose-negative and protein D-negative strains

Research

Temporal changes in BEXSERO® antigen sequence type associated with genetic lineages of Neisseria meningitidis over a 15-year period in Western Australia

The BEXSERO® vaccine which is used to prevent serogroup B disease is composed of four sub-capsular protein antigens supplemented with an outer membrane vesicle.

Research

A Retrospective case-series of children with bone and joint infection from northern Australia

We report osteomyelitis incidence in indigenous children of northern Australia is amongst the highest reported in the world

Research

Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021

Invasive fungal diseases (IFD) are serious infections associated with high mortality, particularly in immunocompromised patients. The prescribing of antifungal agents to prevent and treat IFD is associated with substantial economic burden on the health system, high rates of adverse drug reactions, significant drug-drug interactions and the emergence of antifungal resistance.

Research

Does a major change to a COVID-19 vaccine program alter vaccine intention? A qualitative investigation

On 8th April 2021, the Australian Technical Advisory Group on Immunisation (ATAGI) made the Pfizer-BioNtech (Comirnaty) vaccine the “preferred” vaccine for adults in Australia aged < 50 years due to a risk of thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca vaccination. We sought to understand whether this impacted COVID-19 vaccine intentions.